1. Brenda SPA., et al: Nipah Virus Infection. Journal of Clinical Microbiology.2018:56 (6); 1-10
2. Murrayk., et al. Amorbilli virus that caused fatal disease in horses and humans Science 1995; 268: 94-97.
3. Geisbert TW., et al. Animal challenge models of Henipavirus infection and pathogenesis. Curr. Top. Microbiol Immunol 2012; 359, 153-177.
4. Tan KS, et al. Epidemiological aspects of Nipah virus infection. Neurol J South East Asia 1999. 4: 77-81.
5. Parashar U D., et al. Case control study of risk factors for human infection with a new zoonotic Nipah virus during a 1998-1999 outbreak of Nipah virus encephalitis in Malaysia. J Infect Dis 2000; 181: 1755-9.
6. Chew M H., et al. Risk factors for Nipah virus infection among abattoir workers in Singapore. J Infect Dis 2000; 181:1760-1763.
7. Chau KB., et al. NiV: A recently emergent deadly paramyxovirus Science2000; 288: 1432-1435.
8. Goldsmith CS., et al. Ultra structural studies of Nipah Virus, a newly emergent paramyxovirus, using thin section, negative stain, immune gold, and in situ hybridization electron microscopy. Microsc Microanal 2000; 6: 644-5.
9. RosellaF.,etal.Rapid and Low-Cost Tools Derived from Plants to face Emerging Re-emerging Infectious Diseases and Bioterrorism Agents .In Defence Against Bioterrorism, Springer,Dordrent.2018: 123-139.
10. Looi LM., et al. Lessons from the Nipah virus outbreak in Malaysia. Malays J Pathol 2007; 29:63-67.
11. G. Chinna Devi., et al. Nipah Viral Infection: An Emergency Outbreak Situation. Asian Journal of Pharmaceutical Research.2018; 8 (4)249-254.
12. Aishwarya S. Ambat., et al: Nipah Virus: A review on epidemiological characteristics and outbreaks to inform public health decision making. Journal of Infection and Public Health, 2019.
13. JunsukeShirai., et al: Nipah Virus Survey of Flying Foxes in Malaysia, 2007: 68-78.
14. Broader CC., et al. A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral Res 2013; 100 (1):8-13.
15. Abdullah., et al. Henipa virus encephalitis. Handbook of Clinical Neurology 2014; 123: 663-70.
16. Chau KB., et al. Fatal encephalitis due to NiV among pig-farmers in Malaysia.Lancet1999.354: 1257-1259.
17. Luby SP. The pandemic potential of Nipah virus. Antiviral Res2013; 100 (1): 38-43.
18. Amal N M., et al. Risk factors for Nipah virus transmission, Port Dickson, Negeri Sembilan, Malaysia: results from a hospital-based case –control study. Southeast Asian J Trop Med Public Health 2003; 31(2): 301-6.
19. Sazzad HMS., et al. Nipah virus infection outbreak with nosocomial and corpse-to-human transmission, Bangladesh. Emerg Infect Dis 2013; 19 (2): 210-7.
20. Luby SP., et al. Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001-2007.Emerging Infectious Diseases 2009; 15: 1229-1235.
21. Nipah virus: Epidemiology, outbreaks and guidance, published on 30 May 2018.
22. Pragya D., et al: Short report: Detection of Nipah Virus RNA in Fruit Bat from India.2012, 575-578.
23. Ajith Kumar., et al: Deadly Nipah Outbreak in Kerala: Lessons Learned for the Future. Indian Journal of Critical Care Medicine.2018; 22 (7): 475-476.
24. D Sunitha. et al. A Review on Nipah Virus. Asian journal of Pharmaceutical Research.2019; 9(4): 307-311.
25. Kulkarni DD., et al. Nipah Virus infection: current scenario. Indian J Virol 2013; 24 (3): 398-408.
26. Goh KJ., et al. Clinical features of Nipah virus encephalitis among pig farmers in Malaysia. New England Journal of Medicine 2000. 342: 1229-1235.
27. O’Sullivan. et al. Fatal encephalitis due to novel paramyxovirus transmitted from horses. Lancet 1997; 349: 93-95;
28. Wong KT., et al., Human Hendra virus infection causes acute and relapsing encephalitis. NeuroPathol Appl Neurobiol.2009; 35: 296-305.
29. Abdullah S., et al. Late onset NiV encephalitis 11 years after the initial outbreak: a case report. Neurol Asia 2012; 17: 71-74. Reviewed in Wong 2010.
30. Chua KB. Nipah virus outbreak in Malaysia. J Clint Virol 2003; 26(3): 265-75.
31. Chua KB. Risk factors, prevention and communication strategy during Nipah virus outbreak in Malaysia. Malays J Pathol 2010; 32 (2): 75-80.
32. Chattu VK., et al. Nipah virus epidemic in southern India and emphasizing “One Health” approach to ensure global health security. Fam Med Prim Care 2018; 7(2): 275-83.
33. Hsu VP., et al. Nipah virus encephalitis reemergence, Bangladesh. Emerg Infect Dis 2004 10: 2082-2087.
34. Paton NI., et al. Outbreak of NiV infection among abattoir workers in Singapore. Lancet1999.354: 1253-1256.
35. Prevention of NiV virus. https://www.cdc.gov/vhf/nipah/prevention/index.html assessed on 14/10/2019.
36. Nahar N., et al. Piloting the use of indigenous methods to prevent NiV infection by interrupting bat’s access to date palm sap in Bangladesh. Health Promot Int 2013; 28: 378-386.
37. Satterfield BA., et al. Status of vaccine research and development of vaccines for Nipah virus. Vaccine 2016; 34(26): 2971-5
38. Ministry of Health and Family Welfare. A fact book the Bangladesh HNP Sector. Dhaka (Bangladesh): Health Economics Unit, Ministry of Health and Family Welfare; 2007.
39. Katherine N., et al. Receptor binding fusion inhibition, and Induction of Cross-reactive Neutralizing Antibodies by a Soluble G Glycoprotein of Hendra Virus June 2005.p-6690-6702.
40. Christopher C., et al. A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral research 2013.100; 8 -13.
41. Bossart KN., et al. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute NiV infection. PLos Pathog 2009; 5(10).
42. Geisbert TW., et al. Therapeutic treatment of NiV infection in nonhuman primates with a neutralizing human monoclonal antibody. Sci Transl Med 2014; 6:242.
43. Mc Eachern JA., et.al. A recombinant subunit vaccine formulation protects against lethal NiV challenge in cats. Vaccine 2008; 26(31): 3842-52.
44. Mungall BA., et al. Feline model of acute NiV infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol 2006; 80(24): 12293-302.
45. Middleton D., et al. Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health. Emerg Infect Dis 2014; 20(3): 372.
46. World Health Organization.”NiV infection”, Surveillance and Outbreak Alert, Pathogenesis and Disease Fact Sheet, World Health Organization Regional Office for South-East Asia Programs and Projects, New Delhi, India.
47. Sidwell, R.W., et al. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide. Science 1972.177, 705-706.
48. Snell, N.J., et al. Ribavirin-current status of a broad spectrum antiviral agent. Expert Opinion. Pharmacotherapy 2001.2, 1317-1324.
49. Pager, CT., et al. Sub cellular localization and calcium and pH requirements for proteolytic processing of the Hendra virus fusion protein. J. Virol 2004.78, 9154-9163.
50. Porotto, M.., et al. Simulating Henipa virus multi cycle replication in a screening assay leads to identification of a promising candidate for therapy.J.Virol 2009 .83, 5148-5155.
51. Hanna., et al. Hendra virus infection in a vetenerian. Med J Aust 185, 562-564.
52. ProMED –mail (2008a). Hendra virus, human, equine-Australia (07): Queensland.
53. Alexander N., et al. General Virology (2010), 91,765-772.
54. Dawes BE., et al. Favipiravir (T-705) protects against Nipah virus infection in the hamster model. Sci Rep 2018; 8(1): 7604.
55. Luby SP., et al. Recurrent zoonotic transmission of NiV into humans, Bangladesh.2001-2007.Emerging Infectious Diseases 2009; 15: 1229-1235.
56. Vigy Elizabeth Cherian., et al. Nipah Virus: A Review. International Journal of Advances in Nursing Management.2018; 6(4): 337-338.
57. Hiromi Horsono., et al. Economic Impact of Nipah Virus Infection Outbreak in Malaysia. Proceedings of the 11th International Symposium on Veterinary Epidemiology and Economics, 2006.